Analyser av FluoGuide

Fluoguide Q3 2024: Gearing up for high-impact catalysts in 2025e - Redeye

Redeye comments on FluoGuide’s Q3 2024 report, following its recent business update on FG001’s planned development in head and neck cancer.

Redeye • 27 Nov 13:13

Fluoguide Q2 2024: Following the plan - Redeye

Redeye comments on Fluoguide’s Q2 2024 report, following its recent cSEK60m directed share issue that came at shareholder-friendly terms.

Redeye • 29 Aug 15:23

Fluoguide: Shareholder-friendly and expected capital raise - Redeye

Redeye comments on Fluoguide raising cSEK60m through a directed share issue.

Redeye • 19 Jun 14:40

Fluoguide Q1 2024: Preparing for next steps - Redeye

Redeye comments on Fluoguide’s Q1 2024 report, following its recent announcement of a collaboration with Intuitive Surgical in head and neck...

Redeye • 30 May 15:13

Fluoguide: Delivering on promises - Redeye

Redeye is encouraged by Fluoguide delivering on its promises by entering a collaboration in head and neck RAS with market leader Intuitive S...

Redeye • 12 Mar 14:38

Fluoguide Q4 2023: Bright prospects - Redeye

Redeye comments on Fluoguide’s Q4 2023 report, with the company having recently communicated a strategy update.

Redeye • 28 Feb 12:48

Fluoguide: Value-accretive strategy shift - Redeye

Redeye updates its estimates following Fluoguide presenting its strategic update.

Redeye • 12 Jan 07:27

Fluoguide: Prioritises HGG, PTT, and HNC in FG001’s clinical development - Redeye

Redeye provides an initial comment on Fluoguide communicating a strategic update for FG001’s clinical development.

Redeye • 08 Jan 13:35

Fluoguide Q3 2023: Spoilt for choice - Redeye

Redeye comments on Fluoguide’s Q3 2023 report, with the company reporting two solid phase II readouts since our last update.

Redeye • 29 Nov 2023 12:17

Fluoguide: Phase IIb HGG data paves FG001’s way to phase III - Redeye

Redeye judges Fluoguide’s phase IIb trial with FG001 in high-grade glioma meeting its primary endpoint aligned with our expectations.

Redeye • 14 Nov 2023 08:40

Fluoguide: Phase IIa head and neck cancer top-line data align with our expectations - Redeye

Redeye notes Fluoguide announcing phase IIa top-line data with FG001 in head and neck cancer.

Redeye • 06 Nov 2023 11:10

Fluoguide Q2 2023: Closing in on high-impact catalysts - Redeye

Redeye comments on Fluoguide’s Q2 2023 report as top-line data from the company’s phase IIb trial in high-grade glioma are just around the c...

Redeye • 30 Aug 2023 13:47

Fluoguide: cSEK15m directed share issue increases financial flexibility - Redeye

Redeye is encouraged by Fluoguide carrying out a smaller directed share issue of cSEK15m in gross proceeds.

Redeye • 06 Jul 2023 07:33

Fluoguide: First of three phase II top-line readouts for 2023e in the books - Redeye

Redeye comments on Fluoguide posting solid phase IIa NSCLC data, providing the first out of three phase II top-line readouts that the compan...

Redeye • 08 Jun 2023 09:16

Fluoguide Q1 2023: A watched pot never boils - Redeye

Redeye comments on Fluoguide’s Q1 2023 report as we close in on multiple high-impact catalysts in 2023e.

Redeye • 01 Jun 2023 07:14

Fluoguide: Phase II readouts drawing closer - Redeye

Redeye comments on Fluoguide providing an update on its clinical trial progress.

Redeye • 25 May 2023 07:30

Fluoguide Q4 2022: Slightly shifted timelines but equity story remains unchanged - Redeye

Redeye comments on Fluoguide’s Q4 2022 report as we enter a catalyst-rich 2023e for the company.

Redeye • 01 Mar 2023 07:46

Fluoguide: Critical catalysts for FG001 in 2023e - Redeye

Redeye comments on Fluoguide’s Q3 2022 report at a time when the company is approaching multiple critical catalysts in the coming 12 months.

Redeye • 24 Nov 2022 12:11

Fluoguide: NSCLC interim data aligns with our expectations - Redeye

Redeye comments on Fluoguide posting interim data from its phase IIa trial with FG001 in NSCLC (FG001-CT002).

Redeye • 07 Nov 2022 14:01

Fluoguide Q2: A broadening pipeline - Redeye

Redeye comments on Fluoguide’s Q2 2022 report, and we judge that the company is laser-focused on delivering catalysts that will bring FG001 ...

Redeye • 25 Aug 2022 15:20

Fluoguide Q1 2022: Our comment - Redeye

Redeye briefly comments on Fluoguide’s Q1 2022 report.

Redeye • 31 May 2022 14:32

Fluoguide: FG001 shines again - Redeye

Redeye comments on Fluoguide presenting clinical trial data from its phase I/II trial in aggressive brain cancer.

Redeye • 18 May 2022 10:19

Fluoguide: Part 1 of phase I/II high-grade glioma trial successfully completed - Redeye

Redeye is encouraged by Fluoguide communicating excellent safety and promising early signs of efficacy from the completed first part of its ...

Redeye • 04 Apr 2022 11:01

Fluoguide Q4 2021: Calm Before the Storm - Redeye

Redeye comments on Fluoguide’s Q4 report, following a relatively calm couple of months on the news front.

Redeye • 30 Mar 2022 16:00

Fluoguide: Directed share issue completed - Redeye

Redeye briefly comments on Fluoguide’s directed share issue of some SEK 25m in gross proceeds, announced yesterday evening.

Redeye • 11 Mar 2022 13:39

Fluoguide: Continued progress - SEB

FluoGuide has been demonstrating good progress with its clinical and preclinical programs, and FG001 appears to be exceeding expectations, w...

SEB • 26 Aug 2021 09:15

Börskollen

För dig med koll på börsen